Eric Smith, MD
Psychiatry · Bartlett, TNNPI 1134233745
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.6% of the total across 451 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,101, 2.9 times the $729 reported in 2019. Among psychiatry clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 451 payments — averaging $22.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$1K
- Vanda Pharmaceuticals Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- AbbVie$906
- Johnson & Johnson$882
- Otsuka America Pharmaceutical, Inc.$862
- plus $4K from 19 others
What the payments were for
- Food & beverage$9,70695%
- Education$5505%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 48 | $1,426 |
| Vanda Pharmaceuticals Inc. | 40 | $1,046 |
| Teva Pharmaceuticals USA, Inc. | 37 | $1,022 |
| AbbVie(2 entities) | 53 | $906 |
| Johnson & Johnson | 30 | $882 |
| Otsuka America Pharmaceutical, Inc. | 45 | $862 |
| Lundbeck LLC | 36 | $740 |
| Takeda Pharmaceuticals U.S.A., Inc. | 43 | $722 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 20 | $668 |
| Axsome Therapeutics, Inc. | 13 | $334 |
| Sunovion Pharmaceuticals Inc. | 17 | $304 |
| Idorsia Pharmaceuticals US Inc | 20 | $252 |
| Merck | 14 | $209 |
| Neurocrine Biosciences, Inc. | 9 | $183 |
| E.r. Squibb & Sons, L.L.C. | 7 | $156 |
| Tris Pharma Inc | 3 | $135 |
| Almatica Pharma LLC | 5 | $125 |
| Baxter Healthcare | 1 | $110 |
| Corium, LLC | 2 | $42 |
| Shire North American Group Inc | 2 | $37 |
| Supernus Pharmaceuticals, Inc. | 2 | $27 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $16 |
| Eisai Inc. | 1 | $16 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,374
- ARISTADA$468
- VRAYLAR$355
- Fanapt$344
- CAPLYTA$330
- SPRAVATO$236
- INVEGA TRINZA$141
- REXULTI$125
- QUVIVIQ$121
- ARISTADA INITIO$117
- Quillivant$114
- Quillichew ER$114
- Dyanavel XR$114
- PerClot$110
How this compares
$10,255 in reported general payments places this provider in the 90th percentile of 503 psychiatry providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 34 | $46,408 |
| CaplytaLumateperone Tosylate | 28 | $44,638 |
| BelsomraSuvorexant | 32 | $14,152 |
| ConcertaMethylphenidate Hcl | 11 | $8,585 |
| FetzimaLevomilnacipran Hcl | 11 | $8,575 |
| Divalproex Sodium ErDivalproex Sodium | 91 | $6,792 |
| Lurasidone Hcl | 16 | $3,718 |
| LoxapineLoxapine Succinate | 12 | $3,038 |
| Paliperidone ErPaliperidone | 14 | $3,021 |
| Olanzapine | 46 | $2,997 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 11 | $2,171 |
| Buspirone Hcl | 88 | $1,870 |
| Naltrexone Hcl | 37 | $1,812 |
| Alprazolam | 202 | $1,750 |
| Aripiprazole | 48 | $1,661 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Fetzima | $906 | $54,98245 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $668 | $44,63828 claims |
| MerckBelsomra | $209 | $14,15232 claims |
| Johnson & JohnsonConcerta | $882 | $8,58511 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $1,022 | $3,03812 claims |
| Lilly USA, LLCOlanzapine | $16 | $2,99746 claims |
| Almatica Pharma LLCSertraline Hcl | $125 | $45249 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 503 psychiatry providers in Tennessee.
Other psychiatry in Bartlett
- Rakesh AminNashville$3M
- Brian BonfardinJohnson City$2.6M
- John FenleyJohnson City$1.4M
- David SnowMaryville$605K
- Karthi NamasivayamKnoxville$225K
- Robert JamiesonNashville$141K
- George BrownJohnson City$91K
- Sricharan MoturiFranklin$82K
- Michelle CochranNashville$74K
- Daniel BoydMemphis$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.